2028 Pharmacokinetics Trials Virus 
Drug Discovery World
AUGUST 10, 2022
And now, with more than 600 CAR T trials recruiting or ongoing, these cells represent a majority of the cellular immunotherapies in development today. CAR T cells are made by transfecting T cells with a transgene that encodes the CAR protein using either a virus, a transposon system, or mRNA. Training T cells to target tumours.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. BNT162 mRNA-based Vaccine Program.
Expert insights. Personalized for you.
246 
Let's personalize your content